Recent Updates in the Management of HR+ HER2-ve Breast Cancer
01 Feb, 24 Icon
01 Feb, 24
13 Icon
13
Mic Icon

Dr Jyoti Wadhwa

Dr. Shruti Kate

Dr. Mubarkunnisa Tonse

Dr. Aasma Pathan

Dr. Reshma Puranik

Overview
Worldwide, breast cancer is the most diagnosed cancer and the primary cause of death in women. In India there are almost >1.7 lakh new cases and >90 thousand deaths from this disease every year as per Globocan 2020 Majority of breast cancer are Hormone receptor positive breast cancer and are diagnosed at advance stage. There are recent advances in management of HR+ HER2- Breast cancer with newer agents like CDK4/6 inhibitors, ADC, PI3K inhibitors, AKT inhibitors , Oral SERDS and other novel agents.

Faculty

Dr Jyoti Wadhwa
affiliationDirector Department of Medical Oncology - Medanta the Medicity, Gurgaon

Dr. Shruti Kate
educationMBBS, MD (Internal Medicine), DM (Medical Oncology)

Dr. Mubarkunnisa Tonse
educationMBBS, MD General Surgery, DM Medical Oncology

Dr. Aasma Pathan
educationMBBS, MD General Medicine,DMedical Oncology Resident Hyderabad

Dr. Reshma Puranik
educationMBBS, DNB - General Medicine, DM - Oncology

Resources